On August 24, 2020 PEEL Therapeutics reported that Researchers have modified a derivative of a plant toxin and linked it to a nanocarrier to create a powerful new therapeutic for childhood tumors (Press release, PEEL Therapeutics, AUG 24, 2020, View Source [SID1234564025]). The new drug and its ability to eliminate chemoresistant tumors in mice is described in a new study published in Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). An exclusive license to develop the drug has been obtained by PEEL Therapeutics, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientists from Children’s Hospital of Philadelphia (CHOP) have been testing the new cancer drug for several years in the laboratory to understand its potential to treat the most aggressive of childhood tumors. The drug is a derivative of camptothecin, a toxin isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree) used for thousands of years for cancer treatment in Traditional Chinese Medicine. Camptothecin poisons cancer cells and has been chemically modified to make chemotherapies like irinotecan and topotecan, drugs used today to treat childhood solid tumors, pancreatic and colorectal cancer. CHOP researchers worked with a pharmacologically enhanced camptothecin derivative called SN22. Their newly engineered drug is made from multiple SN22 molecules reversibly linked to a biocompatible carrier fully eliminated by the body after delivering its payload. In preclinical studies, this new drug accumulates in tumors 50 to 100 times more than irinotecan without causing toxicity or eliciting chemoresistance.

PEEL Therapeutics, a USA-Israeli biotech company, has licensed the new drug from CHOP to prepare an Investigational New Drug submission to the FDA. As highlighted in the paper, the engineered SN22 produced remarkably long-term remission in 80 to 100% of mice with drug-resistant tumors including neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma. Many tumors completely disappeared after 4 doses and remained undetectable for over 6 months without ever returning. The CHOP study published in Cancer Research demonstrated that the drug is protected from enzymes that inactivate camptothecins and unaffected by cell transporters that pump out chemotherapies from cancer cells. Importantly for children, the paper describes that the engineered drug appears to have a better safety profile with less toxicities than irinotecan.

PEEL Therapeutics CEO and Co-Founder, Dr. Joshua Schiffman, is a pediatric oncologist and expressed excitement for PEEL’s involvement with this new drug. "At PEEL, we look for therapies inspired by evolution. The SN22 nanoparticle is the perfect example of a drug at the intersection of nature and technology. The increased delivery and decreased toxicities of this drug may offer very important advantages to patients with solid tumors, including children and adults."

PEEL Therapeutics, Inc. is an emerging biotech that delivers evolution-inspired medicines to improve patient lives. The PEEL pipeline originates from assets inspired by the evolution of elephants, plants and humans for the treatment of cancer and inflammatory diseases, including COVID-19. PEEL is supported by private investors and philanthropic charities including Closer To Cure Foundation, Animal Cancer Foundation, and Soccer for Hope Foundation. The company is located in Salt Lake City, Utah and Haifa, Israel.

On August 24, 2020 Sihuan Pharma reported its innovative drug subsidiary, Xuanzhu Biopharma, completed a $116 million Series A round financing from SDIC (Press release, XuanZhu Pharma, AUG 24, 2020, View Source [SID1234564024]). SDIC will own 18.6% of Xuanzhu, which is valued at $624 million. Sihuan said Xuanzhu is differentiated from other startups by having complete drug R&D capability along with the parent company’s production and commercialization support. The company has two candidates in late-stage trials: birociclib, a CDK4/6 inhibitor for advanced breast cancer and janagliflozin, an SGLT2 inhibitor for diabetes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 24, 2020 Merck reported that it is set to spend £1 billion ($1.31 billion) on a new unifying early research hub in England’s capital city (Press release, Merck & Co, AUG 24, 2020, View Source [SID1234563991]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new hub, which will bring together staffers from across the region to a central hub in London, will be the company’s first early-stage R&D center outside of its native U.S. The focus will be on diseases of aging, predominately in neuroscience, an area with high risk but major unmet need.

Merck had made moves to create the hub back in 2017, a year after the U.K. voted to leave the EU, and was hailed by politicians as a positive investment.

It has been somewhat delayed, given how tight space is in London (the same issues New York has with lab space) and it wanting to be in the life sciences hub by the Francis Crick biomedical research institute in north London. Merck, known as MSD in Europe, already has a major five-year neuro R&D pact with the Crick Institute.

It will be called, quite simply, the London Discovery Research Centre, and it should be up and running by 2025, with work starting late next year, should it cut through the red tape. On top of the moving scientists and staffers from its other areas into the center, it also expects to create about 120 new jobs for scientists and technicians.

In all, it expects to employ 800 people at the 25,000-square-meter site and to spend £1 billion all told on the hub.

"We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure," said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times.

On August 24, 2020 Compass Therapeutics, Inc. a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, reported the publication in the journal Science of preclinical data supporting CTX-2026, the Company’s novel anti-CD277 antibody product candidate (Press release, Compass Therapeutics, AUG 24, 2020, View Source [SID1234563985]). The paper describes the discovery and preclinical characterization of CTX-2026, a fully human antibody that binds to the CD277 antigen expressed on members of the butyrophilin family, including BTN3A1, and has been shown to engage two T cell subsets, gamma delta and alpha beta, to overcome the immunosuppressive tumor microenvironment associated with ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper entitled "BTN3A1 Governs Antitumor Responses by Coordinating Alpha Beta and Gamma Delta T-Cells," was co-authored by Jose R. Conejo-Garcia, M.D., Ph.D., and other researchers at Moffitt Cancer Center, researchers from The Wistar Institute, and Compass Therapeutics scientists.

"Ovarian cancer has been one of the most difficult cancers to treat, with a significant unmet need in the United States and around the world. I am encouraged by these data which not only suggest that BTN3A1 may play an important role in ovarian cancer but also demonstrate that CTX-2026 binding to BTN3A1 overcame the immunosuppressive microenvironment of ovarian cancer and delayed malignant progression in preclinical tumor models," said Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer at Compass Therapeutics. "We are excited about this program and its potential to deliver a novel, immune-oncology therapeutic candidate."

"This research demonstrates that targeting BTN3A1 orchestrates cooperative killing of established tumors by alpha beta and gamma delta T cells, and could enable novel interventions for malignancies resistant to existing immunotherapies," said Dr. Conejo-Garcia, Co-Leader of the Immunology Program and Chair of the Department of Immunology, Moffitt Cancer Center.

Highlights from the publication include:

BTN3A1 is overexpressed in malignant ovarian cancers, compared to benign ovarian tumors and normal tissues. Consistent with its immunosuppressive role, higher average BTN3A1 expression in samples from 200 ovarian cancer patients with clinical data was associated with significant reduction in patient survival.
CTX-2026, an anti-CD277 antibody, elicited coordinated alpha beta and gamma delta T cell responses, preventing alpha beta T cell inhibition while inducing gamma delta T cell activation to suppress the growth of established ovarian tumors in preclinical models.
CTX-2026 antibodies transform BTN3A1 from an immunosuppressive to an immunostimulatory mediator, restoring pre-existing anti-tumor immune responses in immunocompetent syngeneic mouse models.
Targeting CD277 by CTX-2026 was associated with greater activity than a PD-1 blocker in the orthotopic xenograft and syngeneic models of ovarian cancer.

On August 24, 2020 Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, reported a private financing of approximately $155 million of convertible notes, with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments (Press release, Kronos Bio, AUG 24, 2020, View Source [SID1234563984]). The financing was led by Perceptive Advisors and included funds and accounts managed by BlackRock, Inc., funds affiliated with Casdin Partners, Commodore Capital, EcoR1 Capital, Fidelity Management and Research Company, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Woodline Partners, and a large diversified asset manager on the west coast, as well as existing investors including GV (formerly Google Ventures), Invus, Nextech Invest, Omega Funds, Polaris Partners, and Vida Ventures, LLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We appreciate the strong support from this group of investors and believe this capital will help propel Kronos through our upcoming period of clinical development," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. "Importantly, this capital will help advance our lead spleen tyrosine kinase (SYK) inhibitor, which we recently acquired from Gilead, including potentially into a registrational trial in 2021. It will also help us advance our second lead pipeline candidate, KB-0742, a differentiated CDK9 inhibitor, into a Phase 1/2 clinical trial for treatment of MYC-amplified solid tumors, as well as to further invest in our product discovery engine to drive multiple oncology programs targeting dysregulated transcription factors."

Jefferies LLC acted as the sole placement agent for the financing.